Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.

"Be the change you wish to see in the world..." Gandhi

Our Beneficiaries

  • University of AZ Research Centers
    University of AZ Research Centers
  • “One of the great movements in my lifetime among educated people is the need to commit themselves to action. Most people are not satisfied with giving money; we also feel we need to work.”

    — Peter Drucker

Brain Tumor News

Toca 5 trial uses viral gene technology to target recurrent brain cancer is currently underway. The trial is being conducted at 67 sites across the United States, Canada, Israel and South Korea.

Researchers tracked genomic alterations detected in patient samples during tumor cell evolution in culture, in patient-derived xenograft (PDX) mouse models from the cultures, as well as before and after treatment in patients. The team reports that tumor progression was often driven by cancer-promoting genes, known as oncogenes, on extrachromosomal pieces of DNA.

“Brain tumors in dogs and humans are remarkably similar,” said Renee Chambers, professor in the Department of Neurosurgery at UAB School of Medicine. “They share similar rates of incidence and mortality, and they share similar symptoms such as seizures, which is often the first symptom observed in both humans and dogs. Treatment is very much the same too, with surgery, radiation and chemotherapy the standard of care.”

Researchers used an experimental molecular therapy in preclinical laboratory tests to effectively treat several types of deadly pediatric brain cancer and now propose advancing the treatment to clinical testing in children. The cancers include intrinsic pontine glioma (DIPG), high-grade glioma (HGG) and high-risk medulloblastoma (MB).

In mice, a fatal brainstem tumor was cleared by injecting it with engineered T cells that recognized the cancer and targeted it for destruction. The discovery is moving to human trials.

Specific biomarkers have been identified that could help assess the likelihood and severity of the recurrence of malignant glioma, a highly aggressive form of brain cancer, according to a study.

View Previous News Articles - Click Here!